Previous 10 | Next 10 |
Would you want to invest in a biotech with a successful product, surging revenue, and barely any debt? And would your answer change if you heard that the stock's price is less than $7 per share? Hopefully, your answers are "yes," and "no." For investors eyeing Amarin Corporation (...
Following the EU approval for Vazkepa (icosapent ethyl) to treat high-risk cardiovascular patients, Amarin Corporation ([[AMRN]] -1.7%) today updated on its plans for the commercial launch of the treatment in the region.The market launch will be rolled out in Germany before the end ...
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs with initial top priority on Germany VAZKEPA commercial launch in German...
Finding amazing stocks under $10 can be tricky. Last year, I hit the jackpot with Novavax (NASDAQ: NVAX) , buying shares at $4, and then riding the stock all the way up to $300 a share earlier this year. Can I replicate my Novavax success? That would be nice. Here are two stocks...
Shares of Amarin (NASDAQ: AMRN) closed 3.9% higher on Tuesday, after there was some good news from across the Atlantic Ocean regarding the only product the company has on the market. That drug, Vascepa, is used to reduce the risk of stroke and heart attacks in patients taking st...
Amarin Corporation (AMRN) has added ~4.9% in the pre-market after announcing that the European Commission has approved its marketing application for Vazkepa (icosapent ethyl) to treat high-risk cardiovascular patients.Vazkepa is now indicated to reduce the risk of cardiova...
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as studied in REDUCE-IT ® 1, 2 DUBLIN, Ireland and BRIDGEWATER, N.J., Marc...
David Einhorn's 13F stock portfolio value increased from $1.22B to $1.66B this quarter. Greenlight increased Atlas Air Worldwide, Teck Resources, and Resideo Technologies while reducing AerCap Holdings, Chemours, and NCR Corp. during the quarter. The largest three positions are at...
Amarin Corporation ([[AMRN]] +1.3%) has announced two new recommendations for its lead product Vascepa (icosapent ethyl) in Canada and Egypt.Vascepa is now included in the 2021 Canadian Cardiovascular Society Guidelines and Egyptian Heart Journal’s Practical Guidance in Lipid...
Recent recommendations or guidances, from Canada and Egypt, expand the global recognition of this important therapy and its demonstrated favorable outcomes study results DUBLIN, Ireland and BRIDGEWATER, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) t...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...